ALGS

Aligos Therapeutics, Inc. ALGS

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,894 of 2,925

Why it scores 8Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-1.50M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$13.23M total
Deep Track Capital, LP
$2.56M0.0%
Alyeska Investment Group, L.P.
$2.38M0.0%
Sio Capital Management, LLC
$1.89M0.0%
MARSHALL WACE, LLP
$1.42M-7.7%
Woodline Partners LP
$1.02M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$1.01M-1.5%
BAKER BROS. ADVISORS LP
$479.2K0.0%
Hillhouse Capital Advisors, Ltd.
$439.9K0.0%
D. E. Shaw & Co., Inc.
$383.5K+505.4%
UBS Group AG
$346.1K+61.9%
GEODE CAPITAL MANAGEMENT, LLC
$272.3K-5.6%
JANE STREET GROUP, LLC
$187.0KNew
BlackRock, Inc.
$174.8K+132.3%
VANGUARD FIDUCIARY TRUST CO
$165.1K+0.6%
DIMENSIONAL FUND ADVISORS LP
$121.4KNew
Verition Fund Management LLC
$109.0K0.0%
Trexquant Investment LP
$71.2KNew
RENAISSANCE TECHNOLOGIES LLC
$62.3K-89.2%
Rockefeller Capital Management L.P.
$57.7K0.0%
Federation des caisses Desjardins du Quebec
$26.8K+389.5%
Golden State Wealth Management, LLC
$15.4K0.0%
ROYAL BANK OF CANADA
$12.0K0.0%
CITIGROUP INC
$10.4KNew
Tower Research Capital LLC (TRC)
$2.1K+452.3%
JPMORGAN CHASE & CO
$1.9K-49.0%
See all 31 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ALGS

Earnings Per Share

13fpro.ai/company/ALGS

Loading ratio trend…

ALGS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Aligos Therapeutics, Inc.'s annual filings on SEC EDGAR.

Aligos Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$2.2M$-24.2M—
FY 2024$3.6M$-131.2M—
FY 2023$6.2M$-87.7M—
Source: ALGS filings on SEC EDGAR →

ALGS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Aligos Therapeutics, Inc. (ALGS): stock profile, AI score and financials

Aligos Therapeutics, Inc. (ALGS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALGS at 8.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,894 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of ALGS by reported 13-F value include Deep Track Capital, Alyeska Investment Group, L.P., Sio Capital Management, based on the most recent SEC filings. ALGS trades on the Nasdaq exchange and files with the SEC under CIK 1799448. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALGS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aligos Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1799448 →